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We report two unrelated patients with overlapping chromosome 2q13 deletions (patient 1 in chr2:111415137-
113194067 bp and patient 2 in chr2:110980342-113007823 bp, hg 19). Patient 1 presents with developmental delay,
microcephaly and mild dysmorphic facial features, and patient 2 with autism spectrum disorder, borderline cognitive
abilities, deficits in attention and executive functions and mild dysmorphic facial features. The mother and maternal
grandmother of patient 1 were healthy carriers of the deletion. Previously, 2q13 deletions were reported in 27 patients,
and the interpretation of its clinical significance varied. Our findings support that the 2q13 deletion is associated with a
developmental delay syndrome manifesting with variable expressivity and reduced penetrance which poses a
challenge for genetic counselling as well as the clinical recognition of 2q13 deletion patients.
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Genome-wide analyses performed on large numbers of
patients have led to the discovery of a multitude of copy-
number variations (CNVs). Segmental duplications predis-
pose genomic regions to recurrent duplication and deletion
by non-allelic homologous recombination (NAHR) events,
some of which cause clinically recognizable core pheno-
types, e.g., Angelman, Prader-Willi, Smith-Magenis and
Williams-Beuren syndromes (reviewed by [1]). Other im-
balances, such as deletions in chromosome 1q21, 15q11,
15q13 and 16p11, present with significant clinical variabil-
ity [2]. For example the chromosome 1q21.1 deletion is
found in patients manifesting one of several features in-
cluding intellectual disability (ID), autism spectrum disor-
ders (ASDs), schizophrenia, microcephaly, cataracts and
congenital heart defects, and it is also detected in healthy
carriers [3, 4]. Similarly the chromosome 16p11.2 deletion
is detected in patients presenting with a variable* Correspondence: kugl@sci.muni.cz; eirik.frengen@medisin.uio.no
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diac defects, speech delay, obesity and dysmorphic features,
as well as in healthy carriers [5–7].
Recurrent genomic imbalances involving the chromo-
some 2q13 (chr2:110-114 Mb) are less described. So far
27 patients carrying a 2q13 deletion have been reported
[8–15]. The patients present with an apparently unspe-
cific and variable clinical phenotype, including develop-
mental delay (DD), ASDs, attention deficits hyperactivity
disorder (ADHD), heart defects and craniofacial abnor-
malities, and several healthy carriers have been identified
[8, 9, 11, 15]. Still, the clinical significance of the 2q13
deletion is not fully determined.
We describe two additional, unrelated patients carrying
a deletion in 2q13. Patient 1 presents with DD, micro-
cephaly and mild dysmorphic features, and patient 2 with
ASD, borderline cognitive ability, attention and executive
function deficits and mild dysmorphic features. The re-
duced penetrance associated with this deletion syndrome
is supported by the identification of two generations of
healthy carriers in one of the families.s article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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Patient 1, a girl, was the first child born to non-
consanguineous healthy Czech parents. The birth was in-
duced at gestational week 41 and the amniotic fluid was
highly turbid. Birth weight was 3500 g (75th centile),
length 50 cm (50th centile), and occipitofrontal circumfer-
ence (OFC) 33 cm (10th centile). Czech consensus an-
thropometric measures were used for this patient [16].
She was born with navel cord hernia and mild dysmorphic
facial features. She walked independently with a clumsy
gait from 2 years of age. From age 2, she experienced fever
convulsions and recurrent respiratory infections. Neuro-
psychological testing at age 21 months revealed mild psy-
chomotor retardation and speech delay, with a vocabulary
of 20 words and articulation problems. Cerebral magnetic
resonance imaging (MRI) and electroencephalography
(EEG) examinations were normal. At the clinical examin-
ation at age 4, her weight was 19.5 kg (90th centile), height
102 cm (25th centile) and she was microcephalic with an
OFC of 46 cm (<3rd centile). Dysmorphic facial features
included broad nasal bridge with low nasal root, pear
shaped tip of the nose and short columella (Fig. 1a), small
chin, low hairline, and low-set ears. She had strabismus.
Metabolic screening of urine was normal except from a
moderately elevated level of 3-hydroxyisovalerate.
Patient 2, a boy, was the only child to a healthy, non-
consanguineous Norwegian couple. He was delivered at
term by an unplanned caesarean section due to his large
size. Birth weight was 4600 g (97th centile), length 56 cm
(>97th centile), and OFC was not recorded. Norwegian
consensus anthropometric measures were used for this
patient [17]. He gained weight adequately, and walked at
16 months. Lack of interest in the surrounding was no-
ticed by the kindergarten staff. He had impaired hearing
due to recurrent middle ear infections, which normalized
after he received drainage tubes bilaterally at 4 years of
age. Cognitive testing at age 7, using Wechsler Intelligence
Scale for Children - third edition 1991 (WISC-III), indi-
cated global developmental delay. Neuropsychological
testing with an extensive panel of tests performed at age
8.5 years showed an overall score in the lower normal
range. He showed deficits in attention and executive func-
tions. Cerebral MRI and EEG examinations were normal.Fig. 1 Patient 1: detail of nose (a) and patient 2: detail of nose (b), mouthAt the clinical examination at age 9, his height was
125.5 cm (3rd centile), weight 25.7 kg (10th centile) and
OFC 52 cm (10th centile). He had delayed fine motor
skills, and impaired balance and coordination. He received
special tutoring at school. He had mild facial dysmorph-
isms, including mild hypertelorism, high and broad nasal
bridge, low-set ears with thick, upper helixes and hypo-
plastic cruz superior, full lips, retrognathia, crowded teeth
and an open mouth appearance (Fig. 1b-d). He also had
mild divergent strabismus and hypermetropia. At age 12
he was diagnosed with pervasive developmental disorder
not otherwise specified (PDD-NOS), and found to have
borderline cognitive functioning. Testing for fragile X syn-
drome was negative. Metabolic screening of urine was
normal.
Methods
Cytogenetic analysis
G-banded karyotyping at 550 band resolution was per-
formed on metaphases from peripheral blood. Array Com-
parative Genome Hybridization (aCGH) analysis was
performed using the Human Genome CGH Microarray
44 K or 244A (Agilent Technologies, Santa Clara, CA) ac-
cording to the manufacturer’s protocol. Samples were sex-
matched with Human Genomic DNA (Promega, Madison,
WI). aCGH slides were scanned with the Agilent Micro-
array Scanner, data obtained using Feature Extraction soft-
ware (v. 6.1.1) and visualized by Agilent Workbench (v.
3.5.14). CNVs were detected by using the ADM-2 algo-
rithm with three neighboring oligos with aberrant intensity
ratios of 0.4 as cut off. All genomic positions were based on
the February 2009 human reference sequence (GRCh37/
hg19) produced by the Genome Reference Consortium.
Quantitative Real-time PCR (qPCR)
Quantitative Real-time PCR (qPCR) was performed using
the SYBR Green Jump-Start Taq ReadyMix PCR kit
(Sigma, Saint Louis, MO). Reactions were run on the ABI
PRIMS 7900 HT Sequence Detection System (Life Tech-
nologies Corporation, Carlsbad, CA) according to the
manufacturer’s recommendations. Amplification levels
were calculated using the ΔΔCt method [18]. Primer se-
quences are supplied in Additional file 1: Table S1.(c) and ear (d). (description in the text)
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performed on chromosomal metaphase spreads from per-
ipheral blood of the maternal grandmother of patient 1,
using the BAC clone RP11-41806 (chr2:111631068-
111793024 bp) as probe. An Olympus BX 61 fluorescence
microscope (Olympus optical company, Tokyo, Japan)
with a 1300D CCD camera (Vds Vosskühler, Osnabrück,
Germany) was used for image acquisition. Image analysis
was performed using the LUCIA-KARYO/FISH software
(Laboratory Imaging, Prague, Czech Republic).
Genomic rearrangement
Both patients show a normal karyotype by G-banding. De-
letions in chromosome 2q13 were detected in both pa-
tients by aCGH. A 1.8 Mb deletion in patient 1 (minimal
deletion between chr2:111415137-113194067 bp and max-
imal deletion between chr2:111406838-113210531 bp)
and a 2.0-2.2 Mb deletion in patient 2 (minimal deletion
between chr2:110980342-113007823 bp and maximal de-
letion between chr2:110970221-113194067 bp) were iden-
tified using a 244 k and 44 k aCGH, respectively (Fig. 2).
The presence of the 2q13 deletions was verified in both
patients by qPCR analysis (Fig. 3), and was shown to be
maternally inherited in patient 1 (Fig. 3). The deletion was
also detected in the maternal grandmother of patient 1
by FISH analysis (Additional file 2: Figure S1). The
qPCR analysis in the father of patient 2 showed normal
results (Fig. 3), but DNA from his mother was unavail-
able. Further qPCR analysis in patient 2 refined theFig. 2 The aCGH results showing the 1.8 Mb and the 2 Mb deletion in 2q1proximal deletion break point to maximally extend to
chr2:110974124 bp, thus not including NPHP1, the
telomeric deletion break point to maximally extend to
chr2:113217195 bp, thus not including TLL, and
chr2:111400720-113097748 bp was confirmed deleted
(Additional file 1: Table S1 and Additional file 3: Figure S2).
The overlap of about 1.7 Mb between the minimal dele-
tions in the patients included nine protein-coding genes
BUB1, ACOX1, BCL2L11, ANAPC1, MERTK, TMEM87B,
FBLN7, ZC3H8 and ZC3H6. In addition, the minimal dele-
tion in patient 1 includes RGPD8 at the telomeric border
and the minimal deletion in patient 2 included RGPD5,
RGPD6, LIMS3 at the proximal border of the 2q13 deletion.
No additional pathological CNVs were detected.
Discussion
The cytogenetic band 2q13 is enriched in clusters of seg-
mental duplications (SDs), which may facilitate NAHR
resulting in deletions and duplications with variable size
and borders in the region chr2:110-114 Mb. These dele-
tions are associated with a developmental syndrome,
manifesting with heterogeneous phenotype and incom-
plete penetrance, which is referred to as 2q13 deletion
syndrome. The high prevalence of the 2q13 deletion in
patients ascertained for intellectual disability or develop-
mental delay (12 out of 15767) compared to controls (1
out of 8329) reported by Cooper et al. indicates that this
deletion is not a benign variant [9], but more research is
needed to establish its pathogenicity.3 in patient 1 (a) and patient 2 (b), respectively
Fig. 3 qPCR detected the chromosome 2q13 deletion in patient 1, her mother, and patient 2 using two independent primer pairs, 2q13_P8 and
2q13_P9, as indicated. Normal DNA levels were detected with the control primer set (Control)
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in 2q13 of 1.8 Mb (patient 1) and 2.0 Mb (patient 2). Pa-
tient 1 showed developmental delay, microcephaly and
mild dysmorphic features, and patient 2 had ASD, bor-
derline cognitive abilities, deficits of attention and
executive functions and mild dysmorphic features. In-
cluding the present report, a total of 29 patients with a
2q13 deletion have been described in the literature [8–15]
(Fig. 4, Additional file 4: Table S2). It is challenging to
compare the clinical features of these patients because
most were reported in studies presenting cohorts of pa-
tients with limited phenotypic information available for
the individual patients. However, 2q13 deletion patients
have been described with a developmental syndrome pre-
senting with a combination of the following features (the
number of patients reported as having the feature is writ-
ten in parenthesis): developmental delay/intellectual dis-
ability (13), dysmorphic features (13), congenital heart
defects (7), hypotonia (7), seizures (5), ASDs (4), macro-
cephaly (4), microcephaly (3), microphallus (3), and
ADHD/ADD (3) (Additional file 4: Table S2). One patient
had schizophrenia without ID, ASD or congenital malfor-
mations [10]. The 2q13 deletion is also characterized by
incomplete penetrance, since unaffected carriers, mostly
parents of affected children, have been identified.
Of the 29 patients so far described, two had a verified de
novo 2q13 deletion (patients 9887950 and 9893017 from
[9]). In 11 the deletion was inherited from a healthy par-
ent, and the inheritance was unknown in 14 patients.
In the two remaining cases (cases 3 and 4 from [13]),
the 2q13 deletion was inherited from parents reported
to have a history of developmental delay. However,
these parents were not included in the total 29 patients
with 2q13 deletions due to the limited information
available. In the family of patient 1 in the presentreport, the 2q13 deletion was identified in two genera-
tions of unaffected female carriers.
In the first two described patients carrying the 2q13
deletion and presenting a pathological phenotype, the
imbalance was inherited from their healthy mother and
therefore concluded to be a benign familial variant [8].
The hypothesis that the 2q13 deletion was pathogenic,
but manifesting with high phenotypic variability and in-
complete penetrance, was suggested after the detection
of the imbalance in three additional patients [11]. Those
were part of a cohort of 2419 patients ascertained for
developmental delay, ASDs or birth defects and investi-
gated by aCGH analysis. Cooper et al. identified 12 pa-
tients with 2q13 deletions among 15767 patients (overall
73 % of cases suffer from ID/DD and/or ASD), and one
2q13 deletion among 8329 controls, supporting the
pathogenicity of the 2q13 deletion [9].
There could be several explanations for the variable
expressivity and reduced penetrance observed for the
2q13 deletion, such as differences in gene content due to
variable deletion break points. It could also be due to
differences in genetic background [19], or a recessive al-
lele unmasked by the deletion [20]. According to the
“two hit” model, the 2q13 deletion could be a risk factor
representing the “first hit”, while the “second hit” could
be an additional genomic imbalance, a single mutation
in a gene functionally related to a gene in the deletion,
or an environmental factor influencing the phenotype
[21]. In support of the “two hit” model, three of the 29
patients with a 2q13 deletion patients were reported to
carry an additional genomic imbalance (case 1 and 3
from [13]; patient #7 from [11]). In the attempt to detect
an unmasked recessive allele, FBLN7 and TMEM87B
were sequenced in two 2q13 deletion patients presenting
with cardiac defects, but mutations were not found in
Fig. 4 A schematic comparison of the chromosome 2q13 deletions identified in patient 1 and patient 2 reported in the present study and in the
27 previously published patients. The telomeric border of the deletion in patient 2 was refined by qPCR (Additional file 3: Figure S2)
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entation and the incomplete penetrance of the 2q13 de-
letion syndrome remain to be elucidated.
Russell et al. depleted the expression of six genes within
the 2q13 region, FBLN7, ANAPC1, TMEM87B, MERTK,
ZC3H8 and ZC3H6, in zebrafish in search for the genes
responsible for cardiac defects and craniofacial abnormal-
ities associated with the deletion syndrome [12]. Cardiac
hypoplasia were seen in animals depleted of TMEM87B
or FBLN7, in addition to craniofacial abnormalities in the
latter, while no such abnormalities were monitored in the
zebrafish depleted of the four remaining genes [12]. This
suggests that heterozygous loss of FBLN7 and TMEM87B
contributes to cardiac defects and craniofacial abnormal-
ities associated with 2q13 deletion syndrome. In addition,
one or both of these genes could be responsible for
additional phenotypes that are not easily monitored in
zebrafish, such as developmental delay, or other genes
within the region could contribute to some of the
remaining phenotypes. For example BCL2L11, encodinga Bcl2-like antiapoptotic protein with a role in neuronal
apoptosis, has been found down regulated in individ-
uals with ASDs [22–24], a diagnosis given to three of
the 29 patients with 2q13 deletion.
Conclusions
Due to limited number of patients reported with smaller,
atypical deletions, and limited functional information
about several of the genes included in the deletion, it is
challenging to establish genotype-phenotype correla-
tions. However, FBLN7 and TMEM87B likely contribute
to the cardiac defects and craniofacial dysmorphisms
[12]. Another gene of interest is BCL2L11, suggested to
play a role in the development of ASDs [22–24]. Despite
several 2q13 deletion patients described and functional
studies performed, the understanding of the genotype-
phenotype correlations and of the mechanisms under-
lying the heterogeneous presentation and incomplete
penetrance in this syndrome is limited. Further func-
tional studies of the 2q13 genes, additional reports of
Hladilkova et al. Molecular Cytogenetics  (2015) 8:57 Page 6 of 7patients with smaller, atypical deletions as well as the
identification of mutations in single genes are needed to
establish the pathogenicity of the deletion and improve
the understanding of the 2q13 deletion syndrome.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
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